INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/03/2023
Back to search
Official data from USPTO
LUYE PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
59
Latest update
09/03/2023
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
11/10/2009
Registration date
04/24/2012
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/11/2022
Last transaction
12/21/2022
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
DAWE III, WILLIAM H
Law office
L80
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of a miscellaneous design on the left, four Chinese characters on the right and the words "LUYE PHARMA" on the top of the Chinese characters.
Holders and representatives
Holders
Shandong Luye Pharmaceutical Co., Ltd.
Representatives
MATTHEW D. ASBELL LADAS & PARRY LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes and drugs for medical purposes namelysodium aescinate injections for the treatment of cerebral edema and edema caused by trauma or operations and of venous back flow obstruction diseasessodium glycididazole injections in the nature of radiosensitizer for the radiotherapy of solid tumors such as head and neck tumorlung canceresophageal cancerreduced glutathione injections for the treatment of alcoholic fatty liveralcoholic liver fibrosisalcoholic liver cirrhosisacute alcoholic hepatitispoisoning by radiotherapydrugs and chemicals; medicinal drinks; pharmaceutical preparationschemico-pharmaceutical preparationschemical preparations for pharmaceutical purposessodium aescinate tablets for the treatment of venous edema and soft tissue swelling due to various causessmectite dispersible tablets and smectite powder sachets for the treatment of acute and chronic bacillary diarrhea of adults and children and for the treatment of pains caused by gulletstomach and duodenum diseases but not used for spasmolysantelcatonin injections for the treatment of bone pains caused by osteoporesisof hypercalaemiaof scleromalacia; biological preparations for medical purposes; tonics being medicineslargetrifoliolious bugbane rhizome tablets for the treatment of the pre-menopausalmenopausal and post menopausal syndrome of womenused to relieve the symptoms of hot sweatingrestlessnessinsomniaflank paindizzinesstinnitus; gelatin for medical purposescompound sodium aescinate gel used to relieve the swelling caused by inflammationdegenerative diseaseswoundsridge pains such as spondylalgialumbagorachialgiasciaticaclosed type acute tissue injurieslesion in the inter-vertebral disksvaricose of veinsperitonitis and phlebitiscapsaicin gel used to relieve arthritis and/or muscle pains caused by osteoarthritisrheumatoid arthritismyelitisfibromyalgia pains caused by sprains to joints; capsules for pharmaceutical purposespantoprazole pellets capsules for the treatment of duodenal ulcergastric ulcer and acute pathological changes of gastric mucosareflux esophagitis and Zollinger-Ellison Syndrome
Publications
History of USPTO decisions and trademark events.
59 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/27/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
07/27/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/11/2023
C71T
CANCELLED SECTION 71
11/11/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
04/24/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
11/28/2019
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
08/12/2019
71AG
REGISTERED-SEC.71 ACCEPTED
08/12/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/21/2019
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
03/14/2019
PR71
POST REGISTRATION ACTION MAILED - SEC.71
01/18/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/15/2018
ES71
TEAS SECTION 71 RECEIVED
10/18/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/15/2016
GPNX
NOTIFICATION PROCESSED BY IB
11/14/2012
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/29/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/03/2012
FIMP
FINAL DISPOSITION PROCESSED
08/02/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/24/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
04/24/2012
GPNX
NOTIFICATION PROCESSED BY IB
02/11/2012
PUBO
PUBLISHED FOR OPPOSITION
02/07/2012
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/18/2012
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/18/2012
NPUB
NOTICE OF PUBLICATION
01/18/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/04/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/03/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/29/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/29/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/29/2011
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/21/2011
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/21/2011
CNRT
NON-FINAL ACTION MAILED
08/09/2011
CNRT
NON-FINAL ACTION WRITTEN
08/08/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/19/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/19/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2011
CNRT
NON-FINAL ACTION MAILED
04/26/2011
CNRT
NON-FINAL ACTION WRITTEN
04/26/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/31/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/31/2011
ALIE
ASSIGNED TO LIE
03/07/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2011
CNRT
NON-FINAL ACTION MAILED
10/07/2010
CNRT
NON-FINAL ACTION WRITTEN
10/07/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/17/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/17/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/17/2010
RFNT
REFUSAL PROCESSED BY IB
06/04/2010
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/27/2010
RFRR
REFUSAL PROCESSED BY MPU
04/27/2010
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/27/2010
CNRT
NON-FINAL ACTION WRITTEN
04/26/2010
MAFR
APPLICATION FILING RECEIPT MAILED
04/23/2010
DOCK
ASSIGNED TO EXAMINER
04/19/2010
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/19/2010
LIMS
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
04/16/2010
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/15/2010
Continuous trademark protection
Get notified about every new filing that threatens LUYE PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.